Below are the most recent publications written about "CD4 Antigens" by people in Profiles.
-
Chakravarty D, Saadi F, Kundu S, Bose A, Khan R, Dine K, Kenyon LC, Shindler KS, Das Sarma J. CD4 Deficiency Causes Poliomyelitis and Axonal Blebbing in Murine Coronavirus-Induced Neuroinflammation. J Virol. 2020 07 01; 94(14).
-
Zhou F, Zhang GX, Rostami A. LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127. Immunol Res. 2017 06; 65(3):630-638.
-
Yadav SK, Gupta RK, Garg RK, Venkatesh V, Gupta PK, Singh AK, Hashem S, Al-Sulaiti A, Kaura D, Wang E, Marincola FM, Haris M. Altered structural brain changes and neurocognitive performance in pediatric HIV. Neuroimage Clin. 2017; 14:316-322.
-
Tao Y, Zhang X, Markovic-Plese S. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). J Neuroimmunol. 2016 09 15; 298:181-8.
-
Hsiao C, Liu M, Stanton R, McGee M, Qian Y, Scheuermann RH. Mapping cell populations in flow cytometry data for cross-sample comparison using the Friedman-Rafsky test statistic as a distance measure. Cytometry A. 2016 Jan; 89(1):71-88.
-
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710.
-
Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat. 2013 Jul; 140(1):23-33.
-
Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol. 2013 Aug; 87(15):8535-44.
-
Danial M, Root MJ, Klok HA. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors. Biomacromolecules. 2012 May 14; 13(5):1438-47.
-
Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN. Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol. 2010 Aug; 63(2):292-308.